diazoxide has been researched along with Insulin Sensitivity in 20 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diazoxide-treated obese and lean animals showed significantly lower postabsorptive plasma insulin concentrations (P < 0." | 5.29 | Modification of insulin resistance by diazoxide in obese Zucker rats. ( Alemzadeh, R; Maturo, J; Slonim, AE; Zdanowicz, MM, 1993) |
| "Diazoxide appears to cause post-receptor insulin resistance in NIDDM, and it may be a useful tool for studying post-receptor binding events." | 5.27 | Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes. ( Greenwood, RH; Hales, CN; Olczak, SA, 1986) |
| "Suppression of serum insulin levels with diazoxide is associated with a decrease in serum testosterone and an increase in serum sex hormone-binding globulin in obese women with the polycystic ovary syndrome." | 5.06 | Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women. ( Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Singh, R, 1990) |
| " We describe a 72-year-old lady who initially presented with episodic hypoglycemia secondary to an insulinoma that was controlled by diazoxide." | 3.69 | Relapse of medically treated insulinoma following the development of thyrotoxicosis: an assessment of potential mechanisms. ( Alberti, KG; Kendall-Taylor, P; Trajano, LR; Walker, M, 1994) |
| "Diazoxide treatment for 10 days was sufficient to increase pulsatile GH secretion in DIO mice before any significant body weight change." | 1.62 | Suppression of hyperinsulinemia restores growth hormone secretion and metabolism in obese mice. ( Chen, C; Chen, Y; Huang, L; Huang, Z; Lu, X; Veldhuis, JD; Zhang, C, 2021) |
| "We hypothesized that hyperinsulinemia precedes the development of insulin resistance and increased adiposity in these mice with a defective adipoinsular axis." | 1.36 | Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic beta-cell leptin signaling. ( Covey, SD; Donald, C; Gray, SL; Jetha, A; Kieffer, TJ, 2010) |
| "Diazoxide-treated obese and lean animals showed significantly lower postabsorptive plasma insulin concentrations (P < 0." | 1.29 | Modification of insulin resistance by diazoxide in obese Zucker rats. ( Alemzadeh, R; Maturo, J; Slonim, AE; Zdanowicz, MM, 1993) |
| "Diazoxide treatment resulted in suppressed insulin release during a 100-g oral glucose tolerance test (insulin area under the curve, 262 +/- 55 nmol/min." | 1.28 | A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. ( Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Plymate, SR; Powers, LP; Rittmaster, RS; Steingold, KA, 1991) |
| "Diazoxide appears to cause post-receptor insulin resistance in NIDDM, and it may be a useful tool for studying post-receptor binding events." | 1.27 | Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes. ( Greenwood, RH; Hales, CN; Olczak, SA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (20.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 3 (15.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Z | 1 |
| Lu, X | 1 |
| Huang, L | 1 |
| Chen, Y | 1 |
| Zhang, C | 1 |
| Veldhuis, JD | 1 |
| Chen, C | 1 |
| Church, D | 1 |
| Cardoso, L | 1 |
| Kay, RG | 1 |
| Williams, CL | 1 |
| Freudenthal, B | 1 |
| Clarke, C | 1 |
| Harris, J | 1 |
| Moorthy, M | 1 |
| Karra, E | 1 |
| Gribble, FM | 1 |
| Reimann, F | 1 |
| Burling, K | 1 |
| Williams, AJK | 1 |
| Munir, A | 1 |
| Jones, TH | 1 |
| Führer, D | 1 |
| Moeller, LC | 1 |
| Cohen, M | 1 |
| Khoo, B | 1 |
| Halsall, D | 1 |
| Semple, RK | 1 |
| Katakam, PV | 3 |
| Gordon, AO | 1 |
| Sure, VN | 1 |
| Rutkai, I | 1 |
| Busija, DW | 3 |
| Domoki, F | 1 |
| Snipes, JA | 2 |
| Busija, AR | 1 |
| Jarajapu, YP | 1 |
| Gray, SL | 1 |
| Donald, C | 1 |
| Jetha, A | 1 |
| Covey, SD | 1 |
| Kieffer, TJ | 1 |
| Alemzadeh, R | 2 |
| Tushaus, KM | 1 |
| Ahrén, B | 1 |
| Pacini, G | 1 |
| Jordan, JE | 1 |
| Tulbert, CD | 1 |
| Miller, AW | 1 |
| Walker, M | 1 |
| Trajano, LR | 1 |
| Alberti, KG | 1 |
| Kendall-Taylor, P | 1 |
| Skrha, J | 1 |
| Hilgertová, J | 1 |
| Justová, V | 1 |
| Slonim, AE | 1 |
| Zdanowicz, MM | 1 |
| Maturo, J | 1 |
| Nestler, JE | 3 |
| Zhou, YP | 1 |
| Cockburn, BN | 1 |
| Pugh, W | 1 |
| Polonsky, KS | 1 |
| Taylor, AE | 1 |
| Blackard, WG | 3 |
| Guzelian, PS | 1 |
| Small, EE | 1 |
| Powers, LP | 1 |
| Matt, DW | 2 |
| Steingold, KA | 1 |
| Plymate, SR | 1 |
| Rittmaster, RS | 1 |
| Clore, JN | 2 |
| Singh, R | 1 |
| Ratzmann, KP | 1 |
| Gutman, R | 1 |
| Basílico, MZ | 1 |
| Mocchiutti, N | 1 |
| Chicco, A | 1 |
| Lombardo, YB | 1 |
| Olczak, SA | 1 |
| Greenwood, RH | 1 |
| Hales, CN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01626443] | Phase 4 | 46 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615] | 80 participants (Anticipated) | Observational | 2007-12-31 | Recruiting | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for diazoxide and Insulin Sensitivity
| Article | Year |
|---|---|
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Insulin-lowering medications in polycystic ovary syndrome.
Topics: Diazoxide; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 2000 |
1 trial available for diazoxide and Insulin Sensitivity
| Article | Year |
|---|---|
Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Diazoxide; Female; Follicular Phase; Humans; | 1990 |
17 other studies available for diazoxide and Insulin Sensitivity
| Article | Year |
|---|---|
Suppression of hyperinsulinemia restores growth hormone secretion and metabolism in obese mice.
Topics: Animals; Body Composition; Diazoxide; Diet, High-Fat; Energy Metabolism; Growth Hormone; Hyperinsuli | 2021 |
Assessment and Management of Anti-Insulin Autoantibodies in Varying Presentations of Insulin Autoimmune Syndrome.
Topics: Adult; Aged; Autoimmune Diseases; Biomarkers; Blood Glucose; C-Peptide; Chromatography, Gel; Congeni | 2018 |
Diversity of mitochondria-dependent dilator mechanisms in vascular smooth muscle of cerebral arteries from normal and insulin-resistant rats.
Topics: Animals; Benzopyrans; Calcium Signaling; Cerebral Arteries; Diazoxide; Imidazoles; Insulin Resistanc | 2014 |
Impaired mitochondria-dependent vasodilation in cerebral arteries of Zucker obese rats with insulin resistance.
Topics: Animals; Cerebral Arteries; Cyclooxygenase Inhibitors; Diazoxide; Disease Models, Animal; Dose-Respo | 2009 |
Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic beta-cell leptin signaling.
Topics: Adiposity; Animals; Blood Glucose; Body Weight; Diazoxide; Eating; Female; Hyperinsulinism; Hypoglyc | 2010 |
Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide.
Topics: Adenylyl Cyclases; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Diabetes Mellit | 2004 |
A novel approach to assess insulin sensitivity reveals no increased insulin sensitivity in mice with a dominant-negative mutant hepatocyte nuclear factor-1alpha.
Topics: Animals; Blood Glucose; Diazoxide; Female; Gene Expression Regulation; Genes, Dominant; Glucose Clam | 2006 |
Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance.
Topics: Animals; Decanoic Acids; Diazoxide; Hydroxy Acids; Immunoblotting; In Vitro Techniques; Insulin Resi | 2007 |
Relapse of medically treated insulinoma following the development of thyrotoxicosis: an assessment of potential mechanisms.
Topics: Aged; C-Peptide; Diazoxide; Female; Humans; Hypoglycemia; Insulin; Insulin Resistance; Insulinoma; P | 1994 |
Insulin action in patients with insulinoma influenced by pharmacological and surgical therapy.
Topics: Adult; Aged; Blood Glucose; Diazoxide; Female; Humans; Hyperinsulinism; Insulin; Insulin Resistance; | 1993 |
Modification of insulin resistance by diazoxide in obese Zucker rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Diazoxide; Energy Intake; Female; Glucose Tolerance Test; In | 1993 |
Basal insulin hypersecretion in insulin-resistant Zucker diabetic and Zucker fatty rats: role of enhanced fuel metabolism.
Topics: Animals; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus; Diazoxide; Enzyme Inhibitors; G | 1999 |
Down regulation of insulin receptors.
Topics: Animals; Concanavalin A; Culture Techniques; Cyclic AMP; Diazoxide; Homeostasis; Humans; Hyperinsuli | 1979 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Topics: Adult; Androstane-3,17-diol; Androstenedione; Diazoxide; Estradiol; Estrone; Female; Glucose Toleran | 1991 |
Insulin resistance in man.
Topics: Diazoxide; Humans; Insulin; Insulin Resistance; Insulin Secretion | 1986 |
Diazoxide prevents the development of hormonal and metabolic abnormalities present in rats fed a sucrose rich diet.
Topics: Animals; Diazoxide; Dietary Carbohydrates; DNA; Glucagon; Heart; Hyperinsulinism; Insulin; Insulin R | 1985 |
Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diazoxide; Fatty Acids, Nonesterified; Female | 1986 |